Addyi Cost in New Jersey 2026: Flibanserin Pricing, Insurance, and Cheaper Alternatives

What Does Addyi Actually Cost in New Jersey in 2026?

The cash-pay price for brand-name Addyi at New Jersey retail pharmacies sits at approximately $880 per month in 2026, matching the Sprout Pharmaceuticals manufacturer list price. That figure reflects a 30-tablet supply of flibanserin 100 mg. Without insurance or a savings program, most patients pay that full amount out of pocket.

Flibanserin received FDA approval on August 18, 2015, as the first oral, non-hormonal prescription treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA label carries a boxed warning about the interaction between flibanserin and alcohol, which can produce severe hypotension and syncope. Prescribers in New Jersey must complete a Risk Evaluation and Mitigation Strategy (REMS) certification before dispensing.

The BEGONIA trial (N=949, published in the Journal of Sexual Medicine, 2014) evaluated flibanserin 100 mg nightly versus placebo over 24 weeks in premenopausal women with HSDD. Patients on flibanserin reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo (P<0.001), alongside meaningful improvements on the Female Sexual Function Index desire domain score. The trial is indexed on PubMed. That evidence base, combined with two additional Phase 3 trials, supported the NDA submission Sprout Pharmaceuticals filed with the FDA.

Understanding price is only the starting point. The sections below break down every reimbursement pathway available to New Jersey patients in 2026.

Does New Jersey Medicaid Cover Addyi?

New Jersey Medicaid does cover Addyi, but coverage requires a prior authorization (PA) for every new prescription. PA approval is not automatic. Prescribers typically need to document that the patient meets the FDA indication (premenopausal, acquired, generalized HSDD), that no reversible medical or psychiatric cause explains the low desire, and that the patient has been counseled on the alcohol restriction.

The HSDD diagnosis itself is recognized in DSM-5 as Female Sexual Interest/Arousal Disorder (FSIAD). New Jersey's Medicaid fee-for-service program and managed care organizations (MCOs) each maintain their own PA criteria, so the exact documentation required varies by plan. Patients enrolled in Horizon NJ Health, Aetna Better Health of New Jersey, or AmeriHealth NJ Medicaid should contact their MCO pharmacy department directly to get the current PA criteria sheet.

According to the FDA-approved prescribing information, flibanserin is contraindicated in patients with hepatic impairment and in those using moderate or strong CYP3A4 inhibitors. Medicaid PA reviewers will check for these contraindications during the approval process.

If a PA is denied, prescribers in New Jersey have the right to file an internal appeal within the MCO and, if that fails, to request an external independent review under New Jersey's Independent Health Care Appeals Program (IHCAP), administered by the New Jersey Department of Banking and Insurance.

Which Commercial Insurance Plans Cover Addyi in New Jersey?

Coverage for Addyi on commercial insurance plans in New Jersey is inconsistent. Some plans list flibanserin on Tier 3 or Tier 4 of their formularies; others exclude it entirely. A 2020 analysis published in JAMA Network Open found that women's sexual health drugs faced formulary exclusion at higher rates than comparable drugs approved for male sexual dysfunction.

Major commercial carriers active in New Jersey include Horizon Blue Cross Blue Shield of New Jersey, Aetna, Cigna, UnitedHealthcare, and AmeriHealth. Each plan's 2026 formulary is available on the New Jersey Department of Banking and Insurance's website or directly through the insurer's pharmacy benefit management (PBM) portal.

Steps to verify your coverage before filling a prescription:

1. Call the member services number on your insurance card and ask specifically whether flibanserin (brand: Addyi, NDC 59630-0580-30) is on formulary.
2. Ask what tier it falls on and what your cost share would be.
3. Ask whether a prior authorization or step therapy requirement applies.
4. If excluded, ask whether an exception request is available through your prescriber.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction note that pharmacological therapy should be considered when psychological and relationship factors have been adequately addressed. Documenting that clinical work-up can strengthen an exception request to a commercial insurer.

Is Compounded Flibanserin Legal in New Jersey?

Compounded flibanserin is legal in New Jersey when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The FDA's 503A framework, codified under the Drug Quality and Security Act of 2013, permits compounding pharmacies to prepare copies of commercially available drugs for individual patients when a prescriber determines a clinical need exists. The FDA's guidance on compounding from commercially available drug products is available on the agency's website.

New Jersey does not prohibit compounding pharmacies from preparing flibanserin as a 503A preparation. The state Board of Pharmacy licenses and inspects compounding pharmacies operating in New Jersey, and out-of-state 503A pharmacies may ship into New Jersey under certain conditions if they hold the appropriate non-resident pharmacy permit issued by the New Jersey Board of Pharmacy.

Cost is the primary reason patients ask about compounded flibanserin. Compounding pharmacies set their own pricing, and fees can range considerably. Some telehealth platforms that partner with licensed 503A pharmacies offer compounded flibanserin at a fraction of the brand-name price. The American Society of Health-System Pharmacists has published standards for sterile and non-sterile compounding that apply to 503A operations.

One caution: the FDA has not reviewed compounded flibanserin for safety or efficacy. Patients and prescribers should verify that the compounding pharmacy is state-licensed, in good standing with the New Jersey Board of Pharmacy, and follows USP <795> standards for non-sterile compounding.

The HealthRX 503A Verification Checklist for New Jersey Patients

Before filling a compounded flibanserin prescription, confirm all four of the following:

1. The pharmacy holds an active New Jersey Board of Pharmacy license (or a valid NJ non-resident pharmacy permit for out-of-state pharmacies).
2. The pharmacy follows USP <795> non-sterile compounding standards.
3. The prescription is patient-specific, issued by a prescriber licensed in New Jersey.
4. No disciplinary actions appear on the pharmacy's state license record, verifiable at the NJ Division of Consumer Affairs license search portal.

Can You Get Addyi via Telehealth in New Jersey?

Telehealth prescribing of Addyi is legal in New Jersey. The state's telehealth law, enacted in 2017 and expanded under P.L. 2021, c.134, permits prescribers holding a valid New Jersey license to evaluate patients via audio-visual telehealth and issue a prescription for flibanserin when clinically appropriate. CMS and state telehealth policy summaries are maintained by the AAFP.

There is one non-negotiable requirement: the prescriber must be enrolled in the FDA's REMS program for Addyi before writing the prescription. The REMS requires that both prescribers and pharmacies be certified, that prescribers counsel patients on the alcohol restriction, and that patients sign a Patient-Prescriber Agreement form. Telehealth visits must include this counseling just as an in-office visit would.

Telehealth platforms operating in New Jersey that offer HSDD evaluation include national services and New Jersey-specific practices. HealthRX connects New Jersey patients with board-certified providers who are REMS-certified for Addyi and can also evaluate whether compounded flibanserin or another approach better fits the patient's clinical profile and budget.

ACOG Committee Opinion 706 supports the use of telehealth for gynecologic care when appropriate clinical standards are met. Telehealth visits for HSDD evaluation generally qualify under that standard when the prescriber conducts a thorough history and screens for contraindications including hepatic impairment, CYP3A4 inhibitor use, and hypotension risk.

How the Sprout Pharmaceuticals Savings Card Works in New Jersey

Sprout Pharmaceuticals offers a copay savings card for commercially insured patients who qualify. The card can reduce out-of-pocket costs to as low as $0 per month for eligible patients, subject to annual program limits. Patients on government-funded insurance (Medicare, Medicaid, CHIP, TRICARE) are not eligible for the manufacturer savings card under federal anti-kickback statute restrictions.

To use the savings card in New Jersey:

1. Confirm you have commercial insurance that covers Addyi (even on a high tier).
2. Enroll at the Sprout Pharmaceuticals website or ask your pharmacist to apply the card at the point of sale.
3. Present the card each month at a participating retail pharmacy in New Jersey.

The savings card is separate from patient assistance programs (PAPs). Uninsured or underinsured patients who do not qualify for the savings card may apply for the Sprout PAP, which can provide Addyi at no cost based on income eligibility criteria. The FDA's guidance on patient assistance programs and co-pay coupon use in federal programs clarifies the legal boundaries for these savings mechanisms.

A 2021 analysis in the Annals of Internal Medicine found that co-pay coupon programs primarily benefit commercially insured patients and have limited reach into underinsured populations. New Jersey patients without commercial insurance should prioritize the Medicaid PA pathway or the manufacturer PAP.

The Clinical Evidence Behind Flibanserin

Three key Phase 3 trials supported Addyi's FDA approval. BEGONIA (N=949) showed significant increases in SSEs over 24 weeks compared with placebo (P<0.001). Published in the Journal of Sexual Medicine in 2014.

The VIOLET and DAISY trials followed similar designs. Pooled data from all three trials, representing over 2,400 women, showed that flibanserin 100 mg nightly produced a mean increase of approximately 0.5 to 1.0 additional SSE per month relative to placebo, along with reduced distress related to low desire. The FDA's medical review memorandum for NDA 022526 details the statistical analyses.

Flibanserin works centrally, not hormonally. It acts as a postsynaptic serotonin 1A agonist and serotonin 2A antagonist, with additional dopamine D4 agonist activity. This mechanism distinguishes it from hormonal therapies like systemic estrogen or testosterone, which target different pathways. A review of central nervous system mechanisms in HSDD published in CNS Drugs outlines this pharmacology.

The most common adverse effects in the trials were dizziness (11.4% flibanserin vs. 2.2% placebo), somnolence (11.2% vs. 3.0%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.5%). These figures appear in the published BEGONIA trial report. Bedtime dosing reduces the functional impact of dizziness and somnolence because most patients are asleep when peak plasma concentrations occur.

The North American Menopause Society (NAMS) position statement on the management of sexual dysfunction in women notes that flibanserin is an FDA-approved option for premenopausal women with HSDD and should be considered in the context of a thorough biopsychosocial evaluation.

"The approval of flibanserin represents a recognition by FDA that hypoactive sexual desire disorder in premenopausal women is a real medical condition deserving of medical treatment," states the FDA approval press release from August 2015. Full text available at FDA.gov.

Alcohol, Drug Interactions, and the Addyi REMS

The FDA's boxed warning for flibanserin centers on the interaction with alcohol. Combining flibanserin with alcohol, even moderate amounts, can cause severe hypotension and loss of consciousness. The REMS requires patients to abstain from alcohol while taking flibanserin. The complete REMS documentation is maintained at the FDA REMS database.

CYP3A4 inhibitors represent the second major interaction class. Fluconazole, ketoconazole, clarithromycin, grapefruit juice, and several HIV protease inhibitors all increase flibanserin plasma concentrations substantially, raising hypotension risk. The FDA drug interactions table for Addyi is published in the prescribing information available at accessdata.fda.gov.

CYP2C19 inhibitors (omeprazole, fluoxetine) also increase flibanserin exposure, though the interaction magnitude is smaller. Prescribers in New Jersey conducting telehealth evaluations must review a full medication list before initiating flibanserin.

A pharmacokinetic study published in Clinical Pharmacology in Drug Development (2016) quantified the alcohol-flibanserin interaction, showing mean systolic blood pressure decreases of up to 28 mm Hg during co-administration. That degree of hypotension can produce syncopal episodes in susceptible individuals.

Comparing Costs: Brand Addyi vs. Compounded Flibanserin vs. Other HSDD Approaches

| Option | Approximate Monthly Cost (NJ, 2026) | Insurance Eligible | REMS Required | |---|---|---|---| | Brand Addyi (retail, cash pay) | $880 | Yes (commercial, Medicaid with PA) | Yes | | Brand Addyi with savings card | $0 (commercially insured, eligible) | Yes (commercial only) | Yes | | Compounded flibanserin (503A) | Varies by pharmacy | Generally no | Yes (prescriber must be REMS-certified) | | Bremelanotide (Vyleesi, SC injection) | ~$1,000/month (WAC) | Yes (commercial, with PA) | No |

Bremelanotide (Vyleesi) received FDA approval in June 2019 as an on-demand subcutaneous injection for premenopausal women with HSDD. The FDA approval and prescribing information are available at accessdata.fda.gov. It is taken 45 minutes before anticipated sexual activity rather than daily, which suits patients who prefer not to commit to a nightly regimen. New Jersey patients who cannot tolerate flibanserin's side effects or cannot abstain from alcohol may find bremelanotide a clinically appropriate alternative.

The International Society for the Study of Women's Sexual Health (ISSWSH) process of care for the identification of sexual concerns in women recommends individualized pharmacological selection based on patient preference, lifestyle factors, and contraindication profile.

Getting a Prescription in New Jersey: Step-by-Step

Patients in New Jersey do not need to visit a specialist's office to start Addyi. The pathway is straightforward.

Step 1. Book a telehealth visit with a REMS-certified provider. HealthRX providers are REMS-certified and licensed in New Jersey.

Step 2. Complete a medical history form before the visit. Include all current medications so the provider can screen for CYP3A4 and CYP2C19 interactions.

Step 3. Attend the audio-visual telehealth visit. The provider will confirm the HSDD diagnosis per DSM-5/FSIAD criteria, rule out reversible causes (depression, hypothyroidism, relationship discord, medication-induced low desire such as from SSRIs), and review the alcohol restriction.

Step 4. Sign the Patient-Prescriber Agreement required by the REMS.

Step 5. Receive the prescription. The provider will send it to your preferred New Jersey pharmacy (retail or 503A compounding, depending on cost preference).

Step 6. Apply the Sprout savings card at the pharmacy if you have qualifying commercial insurance.

The FDA's REMS list of certified pharmacies for Addyi is searchable at accessdata.fda.gov. Confirm your pharmacy is certified before transferring the prescription.

Why Flibanserin Is Still Underutilized Despite FDA Approval

Despite approval in 2015, flibanserin remains underused in clinical practice. A 2019 study in Sexual Medicine (N=3,219 clinicians) found that fewer than 15% of OB-GYNs had prescribed flibanserin in the prior 12 months, citing unfamiliarity with the REMS process and concern about efficacy. The REMS certification process takes approximately 20 minutes and is completed online at the FDA's website. It does not require in-person training.

Prescriber hesitancy combined with insurance barriers has kept prescription volume well below the number of women with diagnosed HSDD in New Jersey. Population estimates from the American Urological Association suggest that HSDD affects approximately 8 to 10 percent of premenopausal women in the United States. Applied to New Jersey's estimated 2.1 million premenopausal women, that implies roughly 168,000 to 210,000 women in the state may meet criteria for the diagnosis.

A 2022 cross-sectional survey published in the Journal of Women's Health found that only 39% of women with symptoms consistent with HSDD had ever discussed sexual desire with a healthcare provider. Access to telehealth evaluation reduces the barrier of having that conversation in a rushed in-person visit.

What to Expect in the First 8 Weeks on Flibanserin

Flibanserin does not produce immediate results. The clinical trials measured outcomes at 24 weeks, and the FDA label advises evaluating response at 8 weeks. Per the prescribing information, if a patient does not report meaningful improvement by 8 weeks, discontinuation should be considered.

During weeks 1 through 2, some patients experience dizziness or somnolence as the central nervous system adjusts. Taking the medication at bedtime reduces functional impairment from these effects. Nausea is most common in the first week and typically resolves without intervention.

Weeks 3 through 8 tend to show gradual improvements in desire-related distress scores. Patients should track SSEs and subjective desire ratings using a simple diary, which also provides documentation the prescriber may use for a Medicaid PA renewal.

A pharmacodynamic study of flibanserin's CNS effects published in the British Journal of Clinical Pharmacology found that the drug's effects on serotonin and dopamine pathways produce gradual neuroadaptive changes rather than acute receptor occupancy shifts, explaining the delayed onset of clinical benefit.

If dizziness is intolerable, the prescriber may consider a temporary dose reduction to 50 mg nightly for 2 weeks before returning to 100 mg, though this approach is off-label and should be discussed directly with the REMS-certified prescriber.